文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

确定 HAM-A 用于轻度、中度和重度广泛性焦虑障碍的截断值。

Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder.

机构信息

Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD 20814, USA.

出版信息

Int J Methods Psychiatr Res. 2010 Dec;19(4):223-32. doi: 10.1002/mpr.323. Epub 2010 Aug 18.


DOI:10.1002/mpr.323
PMID:20718076
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6878292/
Abstract

The aim of the current study was to identify and evaluate cutoffs for mild, moderate, and severe ranges of Hamilton Anxiety Rating Scale (HAM-A) scores. Data were from a four-week randomized trial of treatment for generalized anxiety disorder. Measures included the HAM-A, SF-36, Hospital Anxiety and Depression Scale (HADS), and Clinical Global Impressions of Severity (CGI-S) scale. HAM-A cutoffs were identified based on literature review, expert panel input, and MANOVA models. The optimal cutoff set was evaluated based on association with clinician CGI-S ratings. The sample included 144 patients (56.3% female; 73.6% white; mean age = 35.7 years; mean baseline HAM-A score = 23.7). The optimal HAM-A score ranges were: mild anxiety = 8-14; moderate = 15-23; severe ≥ 24 (scores ≤ 7 were considered to represent no/minimal anxiety). Analysis of variance (ANOVA) models found statistically significant differences among these groups in the SF-36 and HADS. The HAM-A severity ranges closely corresponded to clinicians' CGI-S ratings. The study represents the first step towards developing severity ranges for the HAM-A. These cutoffs should be used with caution and validated in larger samples. If the proposed cutoffs are accepted for general use, they could make results more meaningful and interpretable for researchers, clinicians, and patients.

摘要

本研究旨在确定和评估汉密尔顿焦虑量表(HAM-A)评分轻度、中度和重度范围的截断值。数据来自广泛性焦虑障碍四周随机治疗试验。测量包括 HAM-A、SF-36、医院焦虑和抑郁量表(HADS)和临床总体印象严重度量表(CGI-S)。HAM-A 截断值基于文献回顾、专家小组意见和 MANOVA 模型确定。最优截断值集基于与临床医生 CGI-S 评分的关联进行评估。样本包括 144 名患者(56.3%为女性;73.6%为白人;平均年龄为 35.7 岁;基线 HAM-A 平均得分为 23.7)。最优 HAM-A 评分范围为:轻度焦虑=8-14;中度=15-23;重度≥24(得分≤7 被认为代表无/轻度焦虑)。方差分析(ANOVA)模型发现这些组在 SF-36 和 HADS 中的差异具有统计学意义。HAM-A 的严重程度范围与临床医生的 CGI-S 评分密切相关。该研究代表了为 HAM-A 制定严重程度范围的第一步。这些截断值应谨慎使用,并在更大的样本中进行验证。如果接受提议的截断值用于一般用途,它们可以使研究人员、临床医生和患者的结果更有意义和可解释。

相似文献

[1]
Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder.

Int J Methods Psychiatr Res. 2010-8-18

[2]
Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.

J Clin Psychiatry. 2004-8

[3]
Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study.

CNS Spectr. 2017-4

[4]
Fluoxetine treatment of depressed patients with comorbid anxiety disorders.

J Psychopharmacol. 2002-9

[5]
Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

JAMA. 2000-6-21

[6]
Novel Augmentation Strategies in Major Depression.

Dan Med J. 2017-4

[7]
An evaluation of the anxiolytic SC 48,274 in generalized anxiety disorder (GAD).

Prog Neuropsychopharmacol Biol Psychiatry. 1994-7

[8]
Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder.

Int Clin Psychopharmacol. 2014-9

[9]
Generalized anxiety disorder and the Hamilton Anxiety Rating Scale in Parkinson's disease.

Arq Neuropsiquiatr. 2010-8

[10]
Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depression.

J Affect Disord. 2013-3-18

引用本文的文献

[1]
Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial.

JAMA. 2025-9-4

[2]
Proportion and related factors of depression and anxiety for patients with pulmonary nodules in China: a outpatient-based cross-sectional study.

Sci Rep. 2025-8-31

[3]
Mental Health and Cognitive Outcomes in Patients Six Months After Testing Positive Compared with Matched Patients Testing Negative for COVID-19 in a Non-Hospitalized Sample: A Matched Retrospective Cohort Study.

Int J Environ Res Public Health. 2025-8-9

[4]
Cross-Cultural Differences and Clinical Presentations in Burning Mouth Syndrome: A Cross-Sectional Comparative Study of Italian and Romanian Outpatient Settings.

J Clin Med. 2025-8-16

[5]
Prevalence and correlates of suicide attempts in working-age, first-episode, drug-naïve major depressive disorder patients.

BMC Psychiatry. 2025-8-8

[6]
Hypoactivity of the Prefrontal Cortex During Go/No-Go Task in Patients With Generalized Anxiety Disorder.

Depress Anxiety. 2025-7-28

[7]
Prevalence and pattern of cognitive dysfunction in young adults and middle-aged patients with type-2 diabetes.

J Family Med Prim Care. 2025-6

[8]
The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders compared with diagnosis-specific protocols for anxiety disorders: A three-year follow-up.

J Mood Anxiety Disord. 2023-9-16

[9]
Maternal mental health improvement in ghana: role of green spaces exposure.

BMC Womens Health. 2025-7-5

[10]
Altered perfusion in the locus coeruleus of patients with chronic migraine: a pilot 3D-PCASL study.

Brain Imaging Behav. 2025-6-3

本文引用的文献

[1]
Estimation of symptom-free days in generalized anxiety disorder.

Curr Med Res Opin. 2006-3

[2]
A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.

J Clin Psychiatry. 2006-2

[3]
Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder.

J Clin Psychiatry. 2005-11

[4]
Open-label trial of riluzole in generalized anxiety disorder.

Am J Psychiatry. 2005-12

[5]
Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction.

Arch Med Res. 2006-1

[6]
The efficacy of divalproex sodium in the treatment of agitation associated with major depression.

J Clin Psychopharmacol. 2005-10

[7]
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.

Arch Gen Psychiatry. 2005-9

[8]
A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.

Am J Psychiatry. 2005-7

[9]
Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.

Eur Neuropsychopharmacol. 2005-12

[10]
Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy.

Pain. 2005-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索